Bristol-Myers Squibb News, Bristol-Myers Squibb Quote, BMY Quote

Bristol-Myers Squibb (NY:BMY) Delayed: 58.83 --0 (-0%)

Prev. Close

$58.83

Today 6M 1Y 5Y

Open

$58.83

52 Wk High

$77.12

52 Wk Low

$49.03

Day High

$58.83

Day Low

$58.83

P/E

38.20

EPS

$1.54

Volume

1,015

Friends, Peers and Foes (?): BMS, PFE, AZN, MRK, ABBV (more...)

ALERTS | RSS

Oct 19, 2026 09:28 AM RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'
Oct 19, 2026 06:59 AM Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Oct 19, 2026 01:32 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at HSBC
Oct 13, 2026 08:59 AM Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'
Oct 13, 2026 05:55 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
Oct 12, 2026 07:27 AM Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
Oct 12, 2026 06:55 AM Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
Oct 12, 2026 06:55 AM Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Oct 12, 2026 06:50 AM Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal
Oct 12, 2026 06:50 AM Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Entities mentioned with bmy

View All Entities